Press release
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)
April 14, 2023Business Services
NEW YORK, April 14, 2023 — Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical …
UCB’s Rozanolixizumab and Zilucoplan Phase 3 Generalized Myasthenia Gravis studies published in prestigious The Lancet Neurology Journal
April 13, 2023Business Services
Brussels (Belgium) 13 April 2023 – 07:00 AM (CET) – UCB, a global biopharmaceutical company, today announced that The Lancet Neurology …
Adaptyv Bio creates a new paradigm for protein engineering using generative AI, open-source software and synthetic biology
April 13, 2023Business Services
Lausanne, Switzerland – 13th April 2023; AI tools like ChatGPT are revolutionizing how the world generates text, images and code. …
BioInnovation Institute & Science Prize for Innovation winners announced
April 13, 2023Business Services
COPENHAGEN, Denmark, April 13, 2023 – BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, …
Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting
April 13, 2023Sales and Marketing
Copenhagen, Denmark, 13 April, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) …
ANGLE plc (“the Company”) Pharma Services Contract with Crescendo Biologics
April 13, 2023Business Services
ANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, is delighted to announce that it has signed a …
ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) ACCEPTED FOR USE WITHIN NHS SCOTLAND EARLIER IN THE TREATMENT PATHWAY FOR HER2-POSITIVE METASTATIC BREAST CANCER
April 12, 2023Business Services
Daiichi Sankyo UK Limited and AstraZeneca UK Limited welcome the news that the Scottish Medicines Consortium (SMC) has accepted Enhertu®▼ …
Almirall, the first to assess wellbeing in a dermatology clinical study
April 12, 2023Business Services
BARCELONA, Spain. April 12, 2023 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced the …
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
April 11, 2023Business Services
CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 11, 2023 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), the essential life science …
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
April 11, 2023Business Services
LONDON and RALEIGH, N.C., April 11, 2023 – Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage …
Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.
April 11, 2023Business Services
Leiden, The Netherlands, April 11, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the first commercial …
Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study
April 6, 2023Business Services
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces the opening …
Innova Care Concepts expand their support to the medical negligence sector with the acquisition of Nurture Group Ltd.
April 5, 2023Business Services
Press Release, Wednesday 5th April 2023, London… As part of a long-term strategy to increase its home adaptation services across …
Ipsen’s response to NICE’s decision on Cabometyx® (cabozantinib) for previously treated differentiated thyroid cancer unsuitable for or refractory to radioactive iodine
April 5, 2023Business Services
SLOUGH, UK, 5th April 2023 – Ipsen is disappointed that the National Institute for Health and Care Excellence (NICE) …
First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study
April 5, 2023Business Services
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
